147 related articles for article (PubMed ID: 30121393)
1. An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas.
Miyashita N; Horie M; Suzuki HI; Yoshihara M; Djureinovic D; Persson J; Brunnström H; Lindskog C; Elfving H; Micke P; Saito A; Nagase T
J Thorac Oncol; 2018 Nov; 13(11):1676-1691. PubMed ID: 30121393
[TBL] [Abstract][Full Text] [Related]
2. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
[TBL] [Abstract][Full Text] [Related]
3. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
[TBL] [Abstract][Full Text] [Related]
4. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.
Kosari F; Ida CM; Aubry MC; Yang L; Kovtun IV; Klein JL; Li Y; Erdogan S; Tomaszek SC; Murphy SJ; Bolette LC; Kolbert CP; Yang P; Wigle DA; Vasmatzis G
Oncogene; 2014 Jul; 33(29):3776-83. PubMed ID: 24037524
[TBL] [Abstract][Full Text] [Related]
5. Distinct microRNA Signature and Suppression of ZFP36L1 Define ASCL1-Positive Lung Adenocarcinoma.
Enokido T; Horie M; Yoshino S; Suzuki HI; Matsuki R; Brunnström H; Micke P; Nagase T; Saito A; Miyashita N
Mol Cancer Res; 2024 Jan; 22(1):29-40. PubMed ID: 37801008
[TBL] [Abstract][Full Text] [Related]
6. ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma.
Miyashita N; Horie M; Mikami Y; Urushiyama H; Fukuda K; Miyakawa K; Matsuzaki H; Makita K; Morishita Y; Harada H; Backman M; Lindskog C; Brunnström H; Micke P; Nagase T; Saito A
Cancer Lett; 2020 Oct; 489():121-132. PubMed ID: 32534174
[TBL] [Abstract][Full Text] [Related]
7. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
8. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
[TBL] [Abstract][Full Text] [Related]
10. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
[TBL] [Abstract][Full Text] [Related]
11. TENET 2.0: Identification of key transcriptional regulators and enhancers in lung adenocarcinoma.
Mullen DJ; Yan C; Kang DS; Zhou B; Borok Z; Marconett CN; Farnham PJ; Offringa IA; Rhie SK
PLoS Genet; 2020 Sep; 16(9):e1009023. PubMed ID: 32925947
[TBL] [Abstract][Full Text] [Related]
12. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
[TBL] [Abstract][Full Text] [Related]
13. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
Donakonda S; Sinha S; Dighe SN; Rao MRS
Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
[TBL] [Abstract][Full Text] [Related]
14. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
17. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
18. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of adjacent CpG sites is negatively correlated with the expression of lineage oncogene ASCL1 in pulmonary neuroendocrine tumors.
Truong N; Chun SM; Kim TI; Suh YA; Jang SJ
Tumour Biol; 2017 Jun; 39(6):1010428317706225. PubMed ID: 28621224
[TBL] [Abstract][Full Text] [Related]
20. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis.
Wu S; Wu D; Pan Y; Liu H; Shao Z; Wang M
Pathol Res Pract; 2019 Feb; 215(2):292-301. PubMed ID: 30527357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
